SLFN11 mRNA expression data in the National Cancer Institute Antitumor Cell Line Panel (NCI-60), Cancer Cell Line Encyclopedia (CCLE), and Genomics of Drug Sensitivity in Cancer (GDSC) datasets show that SLFN11 is not expressed in ~50% of cancer cells that exhibit poor response to clinically used DDAs. This evidence concerns the gene SLFN11 and cancer.